CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
Completed
Pfizer
Phase 2
1997-02-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute
myeloid leukemia in first relapse.
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Completed
Pfizer
Phase 2
1998-03-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who
have acute myeloid leukemia that has recurred for the first time following at least 3 months
of complete remission.
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Completed
National Cancer Institute (NCI)
Phase 2
2000-07-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate
cancer cells and either kill them or deliver cancer-killing substances to them without
harming normal cells. Combining more than one drug or combining monoclonal antibody with
chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more
effective for acute myelogenous leukemia.
PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens
in treating patients who have relapsed or refractory acute myelogenous leukemia.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
